Latuda lurasidone: Updated Phase III data

Sumitomo said updated data from the double-blind, Asian Phase III PASTEL trial of lurasidone no longer support approval of the product to treat schizophrenia in Japan. In 439 patients in the modified

Read the full 326 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE